Xenetic Biosciences, Inc. (XBIO) analyst actions
Rating and price-target actions on XBIO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the XBIO overview →
2 measured XBIO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma | Press release | -0.24% | -3.83% | |
| Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma | Press release | +0.90% | +2.69% |
Keep exploring
More XBIO: earnings → · SEC filings → · XBIO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| American Shared Hospital Services (AMS) | 121 | 0.00% | 48% |
| Protagenic Therapeutics, Inc. (PTIX) | 121 | 0.00% | 39% |
| Avenue Therapeutics, Inc. (ATXI) | 120 | 0.00% | 37% |
| CARL ZEISS MEDI UNSP/ADR (CZMWY) | 120 | -0.21% | 21% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.